NVP-BYL719 is novel and specific PI3K inhibitor.NVP-BYL719 has displayed promising results in cancer therapy and is currently under clinical trials.
For research use only. We do not sell to patients.
| Name | Alpelisib(BYL719) |
|---|---|
| Iupac Chemical Name | 1,2-Pyrrolidinedicarboxamide, N1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-, (2S)- |
| Synonyms | BYL-719,NVP-BYL719 |
| Molecular Formula | C19H22F3N5O2S |
| Molecular Weight | 441.47 |
| Smile | CC=1N=C(SC1C1=CC(=NC=C1)C(C(F)(F)F)(C)C)NC(=O)N1[C@@H](CCC1)C(=O)N |
| InChiKey | STUWGJZDJHPWGZ-LBPRGKRZSA-N |
| InChi | InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1 |
| CAS Number | 1217486-61-7 |
| Related CAS |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | crystalline solid |
|---|---|
| Purity | >98% by HPLC |
| Storage | 3 years -20ºCpowder |
| Solubility | 5mg/ml in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |